STL Index for: topical treatment
Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis
The Canadian Skin Management in Oncology Group (CaSMO) developed an algorithm for the reduction of severity and management of acute RD, which follows previous publications from this group that addressed general oncology-treatment related cutaneous adverse events [AEs], prevention, and skin management.
Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).
The update covers: Tazarotene lotion, 0.045% - Arazlo™ (Bausch Health), Anifrolumab-fnia IV use - Saphnelo™ (AstraZeneca), Immune globulin intravenous (human) 10% - Octagam® 10% (Octapharma), Odevixibat capsule - Bylvay™ (Albireo Pharma) and other treatments
Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.
Oral nicotinamide is an affordable over-the-counter supplement with demonstrated benefit in the treatment of a range of skin conditions, most notably AK and NMSC.
This update covers: Gene therapy for DEB (AGLE-102), Golimumab for IV use (Simponi® Aria™), Clascoterone 1% cream (Winlevi®), Triplet melanoma therapy (Tecentriq® + Cotellic® and Zelboraf®), Ustekinumab for SC use (Stelara®), Calcipotriene + betamethasone dipropionate cream (Wynzora®), Abametapir 0.74% lotion (Xeglyze™), Sonidegib capsules (Odomzo®) and Halobetasol propionate + tazarotene lotion (Duobrii™).
The Impact and Treatment of Psoriasis in Manitoba Dermatology Clinics: The Case for Calcipotriol-Betamethasone Dipropionate Foam Formulation
In a small real-world patient case review study, dermatologists tested the efficacy, safety and patient preference of Enstilar®, a calcipotriol-betamethasone dipropionate (Cal/BD).
The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.
In two large randomized vehicle-controlled 12-week trials and in a 52-week open label study of moderate-to-severe acne at the face and trunk in subjects aged 9 years and older, trifarotene 50 μg/g cream demonstrated efficacy, safety, and cutaneous tolerability.
Efinaconazole in the Treatment of Onychomycosis: Managing Patient Expectations and Promoting Compliance
Onychomycosis, also known as tinea unguium, is a progressive fungal infection of the nails resulting in discoloration, nail plate thickening, and onycholysis. Efinaconazole 10% solution is an effective and convenient topical antifungal treatment for onychomycosis, with toenail mycological cure rates between 53.4% and 55.2% and complete cure rates between 15.2% and 17.8%.
Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.
Evolving understanding of the role of hormones in acne, along with a growing body of data from clinical trials, calls for a reappraisal of the role of hormonal therapy for acne.
Adherence to topical treatment for psoriasis remains a challenge as the daily application creates a significant treatment burden. New topical therapeutic options need to offer a combination of higher efficacy and better patient acceptability, including...
Most people with mild-to-moderate psoriasis manage their disease with topical therapies. However, adherence to topical treatment remains a challenge.. Read about new topical therapeutic options.
Update and discussion on onychomycosis (nail fungus) and Efinaconazole 10%. Recent clinical trial results, and discussion about patient safety profile, special cases like diabetic patients, and cure rates.
An overview and update of skin treatments introduced in 2015: Quick overview of drug name, indications and regulatory status. Deoxycholic acid injection, 5-fluorouracil 0.5% + salicylic acid 10% solution, Adapalene 0.3% + benzoyl peroxide 2.5% gel, and more are covered.
Onychomycosis is a stubborn fungal infection of the nails that can be difficult to manage. Clinical trial data of Tavaborole is considered, as it allows for effective nail penetration compared to ciclopirox and amorolfine lacquers.
The scalp is involved in up to 80% of individuals with psoriasis. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment, but other therapies such as light treatment and systemic drugs including biologics are discussed.
An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.
An overview and update of skin treatments introduced in 2013: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Ingenol mebutate gel (0.015%, 0.05%) (Picato®), Efinaconazole 10% topical solution (Jublia®) and many other drugs are covered.
Nail fungus, left untreated, the infection can spread to other nails and potentially cause further complications. This article reviews efinaconazole 10% as a topical monotherapy. Clinical trial data, mechanism of action, and future treatments are discussed.
Update on Brimonidine tartrate 0.33% topical gel (Mirvaso®), Mechlorethamine gel (Valchlor™), OnabotulinumtoxinA for injection (Botox® Cosmetic), Ustekinumab (Stelara®), Certolizumab pegol (Cimzia®), Infliximab (Inflectra™), Efinaconazole 10% topical solution (Jublia®)
While biologics changed the way psoriasis is treated by providing effective targeted therapy, they are not without limitations. Small molecules are emerging therapeutic options for the treatment of psoriasis.
Hair loss is a widespread complaint that carries a significant psychosocial burden for affected individuals. Androgenetic alopecia (AGA) is the predominant cause of hair loss seen in the dermatology clinic. This article reviews a range of therapies that are available for AGA treatment.
Skin Treatments Introduced in 2012. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US), Ingenol mebutate gel (0.015%, 0.05%) Picato®and more are covered.
An overview and update of skin treatments introduced in 2012: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Adapalene 0.3% gel (Differin®), Tazarotene 0.1% foam (Fabior™), CIP-Isotretinoin capsule Epuris™ (in Canada) Absorica™ (in US) and more drugs are covered.
Androgenetic alopecia (AGA) may affect up to 70% of men and 40% of women at some point in their lifetime. Here we briefly review current therapeutic options and treatments under active investigation.
Acne vulgaris is the most common skin disorder affecting children and young adults in North America. This article discusses combination therapy, and simplifying treatment plans in order to increase patient adherence, which is often a critical problem in treating acne.
This article focuses on topical D3 vitamin analogues for the treatment of psoriasis. Therapeutic efficacy, toxicity, patient adherence, combination therapy, and the family physician's role in psoriasis treatment are covered.
This paper focuses on a comprehensive and practical approach to classifying and managing scars in terms of colour and texture, and discusses topical treatments accessible to family physicians in more detail.
Acne vulgaris is a common chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses the multifactorial nature of acne pathophysiology, therapeutics, and mechanism of action.
Psoriasis and eczema, especially atopic eczema, are two of the most common cutaneous conditions seen by family physicians and dermatologists. This article discusses the etiology of psoriasis and eczema, immunologic abnormalities, and the role of immune mediators.
Acne vulgaris is a chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses pathophysiology, sebum production, keratinization, and the role of P.acnes in acne formation.
12Page 1 of 2